Association study of circulating endothelial cells and clinical outcome of pulmonary hypertension secondary to congenital heart disease
10.3760/cma.j.issn.1673-4912.2015.03.005
- VernacularTitle:循环内皮细胞与先天性心脏病相关性肺高压临床预后关系分析
- Author:
Rui HUANG
;
Mingjie ZHANG
;
Zhuoming XU
- Publication Type:Journal Article
- Keywords:
Pulmonary hypertension;
Congenital heart disease;
Circulating endothelial cells;
Biomarkers
- From:
Chinese Pediatric Emergency Medicine
2015;22(3):165-168,172
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the count of circulating endothelial cells (CECs) between patients with reversible pulmonary hypertension (RPH) and irreversible pulmonary hypertension (iRPH) by flow cytometry in order to find a new biomarker to distinguish RPH from iRPH.Methods Ninety pulmonary hypertension associated with congenital heart disease patients treated in our hospital between September 1,2013 to March 31,2014 were enrolled in this study.According to the mean pulmonary arterial pressure (mPAP) measured by echocardiography in six months after treatment,the patients were separated into 2 groups:iRPH group(mPAP≥50 mmHg),RPH group(mPAP ＜50 mmHg).Results Totally the clinical data of 87 patients were enrolled in the statistic analysis,86 patients finished the follow-up in 6 months after the surgery,1 patient died from pulmonary hypertensive crisis.The count of CECs was not correlated with the extent of pulmonary hypertension(P =0.925).The number of CECs was higher in iRPH group than that of RPH group(0.46‰ vs.0.09‰,Z =-5.021,P =0.000).And also the age of patients in iRPH group was elder than that of patients in RPH group [(43.1 ± 37.4) months vs.(9.3 ± 12.6) months,t =-5.079,P =0.000].Conclusion The count of CECs is significantly increased in iRPH patients.It could be used as one biomarker to distinguish RPH from iRPH.
